Amgen Inc. (AMGN) saw its value increase by 0.23% as the stock gained $0.39 to finish the day at a closing price of $168.05. The stock was lighter in trading and has fluctuated between $133.64-$176.85 per share for the past year. The shares, which traded within a range of $165.57 to $168.07 during the day, are up by 14.3% in the past three months and down by -2.42% over the past six months. It is currently trading 6.04% above its 20 day moving average and 10.45% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $182.88 a share over the next twelve months. The current relative strength index (RSI) reading is 72.06.The technical indicator do not lead us to believe the stock will see more gains any time soon.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The companys products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The companys other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddys Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
State Street Corporation (STT) shares were up in last trading by 2.72% to $81.45. It experienced higher than average volume on day. The stock increased in value by almost 5.1% over the past week and fell -1.78% in the past month. It is currently trading 3.08% above its 50 day moving average and 18.57% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -2.44% decrease in value from its one year high of $83.49. The RSI indicator value of 63.88, lead us to believe that it is a hold for now.
State Street Corporation, through its subsidiaries, provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, including custody; product- and participant-level accounting; daily pricing and administration; master trust and master custody; record-keeping; cash management; foreign exchange, brokerage, and other trading services; securities finance; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; and performance, risk, and compliance analytics. It also provides investment management services, such as investment management, investment research, and investment advisory services to corporations, public funds, and other sophisticated investors, as well as offers active and passive asset management strategies across equity, fixed-income, and cash asset classes. The company offers its products and services to mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments, and investment managers. State Street Corporation was founded in 1792 and is headquartered in Boston, Massachusetts.
Ameriprise Financial, Inc. (AMP) traded within a range of $125.57 to $128.38 after opening the day at $125.58. The company has seen its stock increase in value by 15.92% so far this year. The stock was up close to 1.32% on active volume in last trading session and closed at $127.81 per share. After the recent gain, the stock is currently holding 0.73% above its 52 week high of $128.38 and 63.95% above its 12-month low of $80.39. The shares are up by over 16.02% in the last three months, and the RSI indicator value of 74.4 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.
Ameriprise Financial, Inc., through its subsidiaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The companys Advice & Wealth Management segment provides financial planning and advice, as well as full-service brokerage services primarily to retail clients through its advisors. Its Asset Management segment offers investment management and advice, and investment products to retail, high net worth, and institutional clients through unaffiliated third party financial institutions and institutional sales force. This segments products include U.S. mutual funds and their non-U.S. equivalents, exchange-traded funds, variable product funds underlying insurance, and annuity separate accounts; and institutional asset management products, such as traditional asset classes, separately managed accounts, individually managed accounts, collateralized loan obligations, hedge funds, collective funds, and property funds. The companys Annuities segment provides variable and fixed annuity products to individual clients through affiliated and unaffiliated advisors, and financial institutions. Its Protection segment offers various products to address the protection and risk management needs of retail clients, including life, disability income, and property casualty insurance through advisors and affinity relationships. The company was formerly known as American Express Financial Corporation and changed its name to Ameriprise Financial, Inc. in September 2005. Ameriprise Financial, Inc. was founded in 1894 and is headquartered in Minneapolis, Minnesota.